Literature DB >> 8610922

Cholesterol reduction: weighing the benefits and risks.

J M Gaziano1, P R Hebert, C H Hennekens.   

Abstract

The National Cholesterol Education Program recommends reducing total and low-density lipoprotein cholesterol levels to decrease the risk for coronary heart disease. The available evidence clearly indicates that higher cholesterol levels increase the risk for coronary heart disease and that cholesterol reduction results in corresponding decreases in risk. In contrast, existing data do not strongly support the idea that cholesterol reduction causes increases in any specific nonvascular cause of death. The outcomes of ongoing, large-scale trials will enable existing guidelines to be refined. However, current recommendations, which encourage nonpharmacologic interventions for about 30% of U.S. adults and cholesterol-reducing drugs for about 7% of U.S. adults, seem both justified and warranted.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610922     DOI: 10.7326/0003-4819-124-10-199605150-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  4 in total

1.  Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease.

Authors:  S R Majumdar; J H Gurwitz; S B Soumerai
Journal:  J Gen Intern Med       Date:  1999-12       Impact factor: 5.128

Review 2.  Triglycerides and coronary risk.

Authors:  J M Gaziano
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

3.  Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial.

Authors:  Chih-Chieh Yu; Wen-Ter Lai; Kuang-Chung Shih; Tsung-Hsien Lin; Chieh-Hua Lu; Hung-Jen Lai; Mary E Hanson; Juey-Jen Hwang
Journal:  BMC Res Notes       Date:  2012-05-23

4.  A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population.

Authors:  F Raal; C Schamroth; J Patel; P Becker
Journal:  Cardiovasc J Afr       Date:  2007 Sep-Oct       Impact factor: 1.167

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.